Affimed N.V. (LON:0HL9)
0.0001
0.00 (0.00%)
Feb 12, 2026, 2:35 PM GMT
Affimed Revenue
Affimed had revenue of 164.00K EUR in the quarter ending September 30, 2024, a decrease of -91.62%. This brings the company's revenue in the last twelve months to 5.64M, down -72.92% year-over-year. In the year 2023, Affimed had annual revenue of 13.91M, down -67.39%.
Revenue (ttm)
5.64M EUR
Revenue Growth
-72.92%
P/S Ratio
0.00
Revenue / Employee
74.17K EUR
Employees
76
Market Cap
1.20K GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13.91M | -28.76M | -67.39% |
| Dec 31, 2022 | 42.67M | 1.12M | 2.70% |
| Dec 31, 2021 | 41.55M | 12.69M | 43.99% |
| Dec 31, 2020 | 28.86M | 7.43M | 34.66% |
| Dec 31, 2019 | 21.43M | -2.30M | -9.68% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Kanabo Group | 1.14M |
| Physiomics | 834.16K |
| Imaging Biometrics | 699.86K |
| Trellus Health | 262.03K |
Affimed News
- 9 months ago - US Stocks Edge Higher; Consumer Sentiment Falls In May - Benzinga
- 9 months ago - Affimed Announces Receipt of Nasdaq Delisting Notice - GlobeNewsWire
- 9 months ago - Affimed Announces Filing for the Opening of Insolvency Proceedings - GlobeNewsWire
- 10 months ago - Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting - GlobeNewsWire
- 10 months ago - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting - GlobeNewsWire
- 10 months ago - Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 11 months ago - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 1 year ago - Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire